News

Search:

Astellas' Prostate Cancer Drug Receives Priority FDA Approval

0 Likes

A new drug manufactured by California-based Astellas Pharma promises to help treat aggressive, late-stage prostate cancer that has evaded other treatments, the US Food and Drug Administration (FDA) Read More...

Tags:

Approved

Astellas

Cancer

FDA

Oncology

Priority Approval

Prostate Cancer

Xtandi

FDA Approves Astellas' Bladder Control Drug

0 Likes

The US Food and Drug Administration (FDA) on 28 June approved Astellas Pharma Global Development’s overactive bladder treatment drug Myrbetriq (mirabegron).The drug is used at the 25mg and 50mg dosage Read More...

Tags:

Approval

Astellas

FDA

Myrbetriq

NDA

Overactive Bladder

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

FDA Plans Huge Cardiovascular Registry With Focus on Medical Devices 2 April 2013
In Unprecedented Shift, EU Parliament Proposes Premarket Authorization for Medical Devices 15 April 2013
Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization 28 March 2013
FDA Gets Go-Ahead for Study of DTC Advertising and Social Media 18 April 2013
UPDATED: President's Budget Proposal Calls for Small Increases at FDA, but Big Changes for Industry 11 April 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013
Warning Letter to Company Cites Low Supplies of Toilet Paper 15 May 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

Astellas' Prostate Cancer Drug Receives Priority FDA Approval

FDA Approves Astellas' Bladder Control Drug

Get RF Today